BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 14, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
May 4, 2017
View Archived Issues
Stealth BioTherapeutics initiates phase I/II trial of SBT-20
Read More
ImmunGene regains rights to three antibody-interferon fusion product candidates
Read More
Cancer Targeted Technology creates PSMA inhibitor with improved in vivo characteristics
Read More
Nymox seeks approval of fexapotide triflutate for BPH in five European countries
Read More
Servier and Miragen extend cardiovascular collaboration
Read More
Novel anti-TIGIT antibody OMP-313M32 induces antitumor immune response in vivo
Read More
FDA accepts for review Xeljanz sNDAs for psoriatic arthritis
Read More
Denovo Pharmatech's TLR8 agonist DN-A1 is in late-stage preclinical development
Read More
Bristol-Myers Squibb initiates first-in-human study of BMS-986218 in advanced solid tumors
Read More
YL-13027 is a novel TGFR-1 inhibitor with promising immunotherapeutic properties in vivo
Read More
New phase I trial investigates MK-5160 in type 1 and type 2 diabetes
Read More
Xultophy launched in U.S.
Read More
Celgene reviews highlights of first quarter 2017
Read More
Taiho studies TAS-4466 for multiple myeloma and lymphoma in new phase I/II trial
Read More
Novel selective and potent CDK8 inhibitors show promising anticancer efficacy in vivo
Read More
Novartis initiates phase I trial of NIS-793 with PDR-001 for advanced malignancies
Read More
TaiMed submits ibalizumab BLA to FDA for treatment of multidrug-resistant HIV-1
Read More
AbbVie reviews key events from first quarter 2017
Read More
Poxel reports promising topline data from Japanese phase IIb study of imeglimin for type 2 diabetes
Read More
Bristol-Myers Squibb presents apelin receptor agonists
Read More
OncoTherapy Science compound sensitizes breast cancer cells to doxorubicin via SUV39H2 inhibition
Read More
BioPharmX's phase IIb study of BPX-011 in acne meets primary endpoint
Read More
F. Hoffmann-La Roche AG discovers HBV capsid inhibitors
Read More
Melinta to present subgroup analysis from Baxdela phase III program
Read More
Can-Fite Biopharma set to begin phase II trial of namodenoson in NAFLD
Read More
Novartis exercises license option for emricasan
Read More
First patient dosed in first-in-human phase I/II trial of RGT-100
Read More
Rydapt available for order in U.S.
Read More
Heat Biologics completes acquisition of Pelican Therapeutics
Read More
